|
Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - EMD Serono |
Research Funding - EMD Serono |
Travel, Accommodations, Expenses - EMD Serono |
|
|
Employment - Genesis Research |
|
|
|
Research Funding - Pfizer |
|
|
Employment - Genesis Research |
|
|
|
Stock and Other Ownership Interests - Merck KGaA; Novartis; UCB |
|
|
|
Research Funding - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
|
Stock and Other Ownership Interests - Pfizer |
|
|
Honoraria - EMD Serono; Pfizer/EMD Serono |
Research Funding - Amgen (Inst); Apollomics (Inst); Arcus Biosciences (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HUYA Bioscience International (Inst); Nektar (Inst); Prometheus; Revimmune (Inst); Revimmune (Inst); Revimmune (Inst); Seagen (Inst) |